Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives
- 1 December 2017
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 87, 101-112
- https://doi.org/10.1016/j.ejca.2017.10.010
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2016
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsNature Genetics, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Immune surveillance by the liverNature Immunology, 2013
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Liver antigen-presenting cellsJournal of Hepatology, 2011
- Antigen-presenting cell function in the tolerogenic liver environmentNature Reviews Immunology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Cancer despite immunosurveillance: immunoselection and immunosubversionNature Reviews Immunology, 2006
- Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation.JCI Insight, 1995